Ocata Therapeutics Company Profile (NASDAQ:OCAT)

About Ocata Therapeutics

Ocata Therapeutics logoOcata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. The Company's advanced products are in clinical trials for the treatment of Stargardt's macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. The Company is also developing several pre-clinical terminally differentiated-cell therapies for the treatment of other ocular disorders. Additionally, it has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OCAT
  • CUSIP:
Key Metrics:
  • Previous Close: $8.47
  • 50 Day Moving Average: $8.42
  • 200 Day Moving Average: $6.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.29
  • P/E Growth: 0.00
  • Market Cap: $N/A
Additional Links:
Companies Related to Ocata Therapeutics:

Analyst Ratings

Consensus Ratings for Ocata Therapeutics (NASDAQ:OCAT) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.25 (2.60% downside)

Analysts' Ratings History for Ocata Therapeutics (NASDAQ:OCAT)
Show:
DateFirmActionRatingPrice TargetDetails
2/23/2016Cantor FitzgeraldReiterated RatingHold$8.50View Rating Details
11/10/2015Raymond James Financial Inc.DowngradeOutperform -> Market PerformView Rating Details
7/10/2015Cowen and CompanyInitiated CoverageOutperformView Rating Details
12/19/2014Maxim GroupReiterated RatingBuy -> HoldView Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Ocata Therapeutics (NASDAQ:OCAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015Q315($0.09)ViewN/AView Earnings Details
8/6/2015Q215($0.19)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocata Therapeutics (NASDAQ:OCAT)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS

Dividends

Dividend History for Ocata Therapeutics (NASDAQ:OCAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocata Therapeutics (NASDAQ:OCAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2015Robert LanzainsiderSell35,000$8.31$290,850.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ocata Therapeutics (NASDAQ:OCAT)
DateHeadline
bloomberg.com logoKey Executives for Ocata Therapeutics, Inc. (NASDAQ:OCAT)
www.bloomberg.com - August 23 at 6:47 PM
News IconResearch report explores the global age related macular degeneration market consumption forecast to 2021 covering ... - WhaTech (NASDAQ:OCAT)
www.whatech.com - July 26 at 6:54 PM
marketexclusive.com logoJapan is Breathing Life into the Stem Cell Space, Astellas Pharma NPV (OTCMKTS:ALPMF) & Pluristem Therapeutics ... - Market Exclusive (NASDAQ:OCAT)
marketexclusive.com - July 21 at 6:54 PM
News IconOcata Therapeutics, Inc. (NASDAQ:OCAT) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:OCAT)
www.engelwooddaily.com - July 18 at 6:44 PM
News IconCrowd Rating and Earnings Recap for Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Telanagana Press (NASDAQ:OCAT)
telanaganapress.com - July 15 at 11:29 AM
News IconOcata Therapeutics, Inc. (NASDAQ:OCAT) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:OCAT)
telanaganapress.com - July 14 at 10:10 AM
News IconTrading Performance and Target Watch for Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Press Telegraph (NASDAQ:OCAT)
presstelegraph.com - July 13 at 6:57 PM
News IconWall Street Ratings and Target Price Views on Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Telanagana Press (NASDAQ:OCAT)
telanaganapress.com - July 8 at 3:05 PM
News IconOcata Therapeutics, Inc. (NASDAQ:OCAT) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:OCAT)
telanaganapress.com - July 7 at 9:32 AM
News IconSell-Side Recommendation & Price Target Projections on Ocata Therapeutics, Inc. (NASDAQ:OCAT) - Telanagana Press (NASDAQ:OCAT)
telanaganapress.com - July 1 at 9:23 AM
fiscalstandard.com logoRecently Issued Stock Ratings For Ocata Therapeutics, Inc. (OCAT) - Fiscal Standard (NASDAQ:OCAT)
www.fiscalstandard.com - July 1 at 9:23 AM
News IconOcata Therapeutics, Inc. (NASDAQ:OCAT) Company Rating and Target Watch - Telanagana Press (NASDAQ:OCAT)
telanaganapress.com - June 30 at 9:28 AM
News IconOcata Therapeutics, Inc. (NASDAQ:OCAT) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:OCAT)
www.engelwooddaily.com - June 28 at 11:27 AM
News IconKeryx Biopharmaceuticals Appoints Two New Board Members - PharmiWeb.com (press release) (NASDAQ:OCAT)
www.pharmiweb.com - June 21 at 10:59 AM
News IconCynata Appoints Paul K Wotton Ph.D. to Board of Directors - irasia.com (press release) (NASDAQ:OCAT)
www.irasia.com - June 9 at 9:32 AM
News IconCantor Fitzgerald Initiates a Buy Rating on Glaukos - Markets.co (NASDAQ:OCAT)
www.markets.co - June 3 at 9:28 AM
News IconStock Review and Earnings Check on Ocata Therapeutics, Inc. (NASDAQ:OCAT) - HNN (NASDAQ:OCAT)
hintsnewsnetwork.com - June 1 at 9:29 AM
News IconOcata Therapeutics, Inc. (OCAT) Recent Analyst Updates - Risers & Fallers (NASDAQ:OCAT)
www.risersandfallers.com - February 7 at 2:45 PM
News IconOcata Therapeutics Inc (OCAT) Profit Expected to Increase - OctaFinance.com (NASDAQ:OCAT)
www.octafinance.com - February 7 at 2:45 PM
News IconRecent Broker Updates On Ocata Therapeutics, Inc. (OCAT) - Risers & Fallers (NASDAQ:OCAT)
www.risersandfallers.com - January 28 at 2:32 PM
stocksdaily.net logoWill Ocata Therapeutics, Inc. (NASDAQ:OCAT) Surprise Analysts This Quarter? - Stocks Daily (NASDAQ:OCAT)
www.stocksdaily.net - January 27 at 2:00 PM
seekingalpha.com logoOcata Shareholder Majority Rejects Astellas Offer As Woefully Inadequate - Seeking Alpha (NASDAQ:OCAT)
seekingalpha.com - January 26 at 2:31 PM
istreetwire.com logoHot Biotech Stocks To Watch Right Now: Sarepta Therapeutics, Inc. (SRPT), Ocata Therapeutics, Inc. (OCAT), Dyax ... - iStreetWire (NASDAQ:OCAT)
www.istreetwire.com - January 25 at 1:48 PM
News IconAstellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics - FierceBiotech (NASDAQ:OCAT)
www.fiercebiotech.com - January 22 at 1:31 PM
News IconSmall investors oppose Ocata sale; $379M offer deemed too low for drug 'worth ... - Worcester Telegram (NASDAQ:OCAT)
www.telegram.com - January 21 at 1:44 PM
capitalcube.com logoOcata Therapeutics, Inc. – Value Analysis (NASDAQ:OCAT) : January 20, 2016 (NASDAQ:OCAT)
www.capitalcube.com - January 20 at 11:25 AM

Social

Ocata Therapeutics (NASDAQ:OCAT) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff